Peptide Atlas · Small molecule

Acetyl-L-Carnitine (ALCAR)

A meta-analysis of double-blind, placebo-controlled trials lasting 3 to 12 months in mild cognitive impairment and mild Alzheimer's disease found a small advantage for acetyl-L-carnitine over placebo on clinical and psychometric measures.

emerging

provisional
PubChem 7045767
2 citations
0 discussions
0 followers
ALC
ALCAR
O-acetyl-L-carnitine
acetylcarnitine
levacecarnine

Follow this molecule Ask the Hunter-Gatherer

What the evidence says

six tiers, never blended

emerging — human data exists, and it is thin or contested

every claim resolves to its source

All 2 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.

Evidence, kept apart

The Atlas never mixes evidence types into one blob. Each claim below carries the tier it actually sits in; an unresolved citation is shown and does not move the page.

Evidence map for Acetyl-L-Carnitine (ALCAR). Tier reflects study design, not enthusiasm.
Claim	Tier	Source
Meta-analysis: small effect of acetyl-L-carnitine over placebo in MCI and mild Alzheimer's disease	emerging	pmid 12598816
Acetyl-L-carnitine increased taxane-induced neuropathy at 24 weeks in a placebo-controlled trial	emerging	pmid 23733756

Unanswered questions

No open questions on file. Either everything about this molecule is known, or nobody has admitted what is not.

Negative findings

failure is information

Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.